Summary The pregnant patient is at risk of several pregnancy-speci¢c pulmonary complications, including amniotic £uid embolism, tocolytic-associated pulmonary oedema and pulmonary oedema complicating pre-eclampsia. In addition, the pregnant state increases the risk of other respiratory complications, particularly pulmonary embolism and gastric acid aspiration.Community-acquired pneumonia occurs in pregnant women at a similar incidence to the non-pregnant population, but the risk of varicella pneumonitis is increased. AIDS-related pulmonary infections should always be considered in this sexually active population.
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Management of the pregnant patient with pulmonary disease must take into account the anatomic and physiological changes a¡ecting the respiratory system in pregnancy. Although management is similar to that in the non-pregnant patient, the welfare of the fetus must be considered in radiological investigations and pharmacological therapy. The pregnant patient with pulmonary disease presents a challenge in view of the altered maternal physiology, the occurrence of diseases speci¢c to pregnancy and the need to consider two patients in all therapeutic decisions. This article will review a number of these issues with a focus on pulmonary physiology, pregnancy-speci¢c pulmonary disorders and other respiratory diseases in the pregnant patient.
PULMONARY PHYSIOLOGY IN PREGNANCY Anatomical e¡ects
The hormonal changes in pregnancy a¡ect the upper respiratory tract, causing airway hyperaemia, oedema, and increased friability. Oestrogen is probably responsible for many of these e¡ects, by producing capillary congestion and hyperplasia of mucous glands.The anatomy of the thoracic cage is altered by both the enlarging uterus as well as from hormonal e¡ects producing ligamentous laxity. The diaphragm is displaced upwards, but the potential loss of lung capacity is largely o¡set by an increase in the anteroposterior and transverse diameters and widening of the subcostal angle (Table 1) . Diaphragmatic function remains normal and diaphragmatic excursion is not reduced. In the pregnant patient near term, the maximum transdiaphragmatic and the maximum inspiratory pressures that can be generated are similar to values generated by non-pregnant patients. The changes to the chest wall return to normal within 6 months of delivery, although the costal angle remains wide.
Pulmonary function tests
The anatomical changes produce a progressive decrease in functional residual capacity (FRC) which is reduced by 10^25% by term. FRC includes the residual volume (RV), which decreases slightly, and the expiratory reserve volume (ERV) which is signi¢cantly reduced. These alterations in lung volume are measurable at 16^24 weeks gestation and progress until term. The increased diameter of the thoracic cage and preserved respiratory muscle function result in a preserved vital capacity, and total lung capacity decreases only minimally by term. Measurements of air£ow are not signi¢cantly a¡ected by pregnancy. Values of forced expiratory volume in 1 second (FEV 1 ) measured serially through pregnancy in normal patients are similar to those obtained in the non-pregnant state. Lung compliance does not appear to be in£uenced by pregnancy, but chest wall and therefore total respiratory system compliance is reduced in the third trimester due to the chest wall changes and increased abdominal pressure. Varying results have been reported in studies of di¡using capacity during pregnancy, likely due to the e¡ects of anaemia and the increase in cardiac output. A small increase may be noted in early pregnancy with a subsequent decrease to normal values by term.
Arterial blood gases
Minute ventilation increases signi¢cantly in pregnancy, beginning in the ¢rst trimester and reaching 20^40% above baseline at term. This is due to an increase in tidal volume of about 30^35%, with only a small increase in respiratory rate. The hyperventilation is mediated by an increase in respiratory drive due to elevated serum progesterone levels, and exceeds that required by the increase in metabolic CO 2 , production of 34^50%. A respiratory alkalosis results, with PaCO 2 falling to 28^32 mmHg (3.7^4.2 kPA), accompanied by compensatory renal excretion of bicarbonate to a level of 18^21mEq/L. Alveolar-to-arterial oxygen tension di¡er-ences are similar to non-pregnant values, and mean arterial PO 2 is generally greater than 100 mmHg (13 kPA) at sealevel throughout pregnancy. Mild hypoxaemia and an increased alveolar^arterial oxygen tension di¡erence may develop in the supine position as FRC decreases near term. Oxygen consumption increases, beginning in the ¢rst trimester and reaching 20^33% above baseline by the third trimester, due to both fetal demands and maternal metabolic processes. The combination of a reduced FRC and increased oxygen consumption results in a lowered oxygen reserve, making the pregnant patient susceptible to the rapid development of hypoxia in response to hypoventilation or apnoea.
Labour and delivery
In active labour, hyperventilation increases, and tachypnoea due to pain or anxiety may result in a more marked respiratory alkalosis. A superimposed metabolic alkalosis can be produced by vomiting and volume depletion. Alkalosis may adversely a¡ects fetal oxygenation by reducing uterine blood £ow. In contrast, severe pain and anxiety may lead to rapid shallow breathing in some patients, resulting in alveolar hypoventilation, atelectasis, and mild hypoxaemia. Adequate pain relief with narcotics or epidural analgesia blunts the ventilatory response and can correct the gas exchange abnormalities associated with active labour.
PREGNANCY-SPECIFIC RESPIRATORY DISORDERS Dyspnoea in pregnancy
Dyspnoea is a common complaint in women with otherwise normal pregnancies.This symptom occurs in 15% of women in the ¢rst trimester, 50% by 19 weeks gestation and 75% by 31 weeks. A number of mechanisms have been proposed, but the most likely explanation is that this represents a normal perception of the increased minute ventilation accompanying pregnancy. Recent studies refute the hypotheses of a change in perception of respiration, or an increased work of breathing related to chest wall distortion. Dyspnoea of pregnancy is usually an isolated symptom and history and physical examination do not reveal evidence of organic disease. This physiological dyspnoea may occur early in pregnancy, does not interfere with daily activities, and tends not to worsen signi¢cantly.
Evaluation requires a detailed history and physical examination, to exclude pathological processes causing respiratory distress (Table 2 ). Investigations such as pulmonary function tests, chest radiograph and echocardiography may be considered.
Amniotic £uid embolism
Amniotic £uid embolism is a rare but often catastrophic obstetric complication with an incidence quoted as between l/8000 and l/80 000 live births and a mortality rate of10^86%.This condition may account for10% of direct maternal deaths. Amniotic £uid embolism is usually associated with labour and delivery, but it may occur during uterine manipulations or related to uterine trauma. The mechanisms are unclear but involve amniotic £uid entering the vascular circulation through endocervical The clinical presentation of amniotic £uid embolism usually involves the sudden onset of severe dyspnoea, hypoxaemia and cardiovascular collapse, often accompanied by seizures. Less commonly, the patient may present with haemorrhage due to disseminated intravascular coagulopathy (DIC) or with acute fetal distress. A signi¢cant proportion (25^50%) of patients may die within the ¢rst hour, and cardiac arrest during this period is common.The diagnosis is usually based on a typical clinical picture.Fetal squamous cells found on cytology of a wedged pulmonary capillary aspirate have been used to con¢rm the diagnosis, but this is not a speci¢c ¢nding. The di¡erential diagnosis in a patient with suspected amniotic £uid embolism is wide, and includes septic shock, pulmonary thromboembolism, placental abruption, tension pneumothorax or a myocardial ischaemic event.
The treatment of amniotic £uid embolism involves routine resuscitative and supportive measures. Adequate oxygenation must be ensured with supplemental oxygen therapy and endotracheal intubation and mechanical ventilation when indicated. Inotropic support is usually required initially to support blood pressure and cardiac output. All pressor drugs may adversely a¡ect the fetus by reducing uterine blood £ow, but should not be withheld when required to support maternal haemodynamics. In view of the inconsistent haemodynamic ¢ndings, invasive monitoring with a pulmonary artery catheter may be of value to guide inotropic therapy. No speci¢c therapy has been shown to be e¡ective, but some authorities suggest a role for corticosteroids.
Survivors of the initial resuscitation are likely to develop the complications of disseminated intravascular coagulopathy (DIC) and adult respiratory distress syndrome (ARDS), which should be anticipated. Furthermore, neurological damage due to hypotension and hypoxaemia is common. Amniotic £uid embolism remains an unpredictable and unpreventable condition with a high mortality rate.
Tocolytic pulmonary oedema
Beta-adrenergic agonists, particularly ritodrine and terbutaline, are used to inhibit uterine contractions in preterm labour. A complication of these agents which is unique to the pregnant state is the development of pulmonary oedema.The frequency of tocolytic-induced pulmonary oedema varies in published series, from less than 1% to 9%. Current data suggest that tocolysis does not signi¢cantly improve neonatal outcome in preterm labour, and the prolonged use of these agents is becoming less common.The mechanism of the pulmonary oedema is not clear but various factors have been implicated. These include myocardial dysfunction caused by exposure to beta-agonists, increased capillary permeability, or the administration of signi¢cant volumes of i.v. £uid, often in response to maternal tachycardia and the hypotension induced by beta-stimulation. Clinical studies, however, have not found evidence to support these mechanisms.Glucocorticoids are often administered in preterm labour to enhance fetal lung maturity and may aggravate £uid retention. It is likely that a combination of the above-mentioned factors, associated with the reduced colloid osmotic pressure occurring in pregnancy, is responsible for producing pulmonary oedema.
The diagnosis is a clinical one, made in the presence of acute pulmonary oedema in the appropriate clinical situation. This di¡erential diagnosis includes cardiogenic pulmonary oedema, amniotic £uid embolism and other conditions. Failure of the pulmonary oedema to resolve in 12^24 h suggests an alternative cause.
The most important aspect of treatment is the discontinuation of the beta-agonist. Further treatment is supportive, including diuresis and the administration of 
Pulmonary oedema due to preeclampsia
Pulmonary oedema may occur in association with preeclampsia, but is relatively uncommon a¡ecting about 3% of pre-eclamptic patients. In general, the pre-eclamptic woman is volume depleted, and pulmonary oedema most commonly occurs in the early postpartum period, associated with aggressive intrapartum £uid replacement. Other factors which play a role in the pathogenesis include reduced serum albumin, increased left ventricular afterload, as well as systolic and diastolic myocardial dysfunction. Increased capillary permeability may also occur, aggravated by concomitant conditions such as sepsis, placental abruption or massive haemorrhage. Pulmonary oedema has also been described in chronically hypertensive, obese pregnant patients who develop pre-eclampsia. Diastolic left ventricular dysfunction occurs due to long-standing hypertension and obesity, with pulmonary oedema being precipitated by the volume overload of pregnancy and the haemodynamic stresses of pre-eclampsia.
The management of pulmonary oedema complicating pre-eclampsia is by standard means, including £uid restriction, administration of supplemental oxygen and diuresis. Invasive monitoring may be valuable if inotropic or vasodilator therapy becomes necessary, or in the presence of renal dysfunction or oliguria. Aggressive diuresis should be avoided, as volume depletion may compromise cardiac output and placental perfusion.
Careful £uid therapy is critical in pre-eclampsia. Volume replacement is often necessary in these volume depleted patients, particularly prior to the administration of anti-hypertensive agents or epidural anaesthesia. However, excessive £uid replacement carries the risk of precipitating pulmonary or cerebral oedema.
Other pregnancy-speci¢c diseases

Peripartum cardiomyopathy
In women who develop left ventricular dysfunction secondary pre-eclampsia or peripartum cardiomyopathy the tachycardia and increased cardiac output occurring during labour and the early postpartum period may precipitate pulmonary oedema. Cardiogenic pulmonary oedema is therefore an important consideration in the di¡erential diagnosis of acute respiratory failure in pregnancy.
Gestational trophoblastic disease
Pulmonary hypertension and pulmonary oedema may complicate benign hydatidiform mole, due to trophoblastic pulmonary embolism. This occurs commonly during evacuation of the uterus and the incidence of pulmonary complications is higher in later gestations. Trophoblastic disease may also cause respiratory disease through the development of choriocarcinoma, which commonly produces multiple, discrete pulmonary metastases, and occasionally pleural e¡usions.
OTHER PULMONARY DISORDERS IN PREGNANCY Asthma
Asthma a¡ects 5^10% of the population and can therefore be expected to involve a similar proportion of women in pregnancy. Pregnancy does not signi¢cantly a¡ect air£ow in non-asthmatic subjects, but in£uences asthma control variably. About one-third of patients deteriorate, and similar proportions improve or do not experience any substantial change. Asthma severity usual returns to prepregnancy levels within 3 months of delivery.
The clinical features of asthma during pregnancy are not di¡erent to those in the non-pregnant patient. However, it may be di⁄cult to di¡erentiate asthma deterioration from dyspnoea of pregnancy by clinical history alone. Objective assessment with pulmonary function tests is essential to assess the presence of air£ow limitation. In the patient with moderate to severe asthma, regular self-monitoring with peak £ow measurements is of value.
The management of asthma during pregnancy does not di¡er to that in the non-pregnant patient. This should include adequate monitoring, avoidance of precipitating factors and education regarding the interactions of pregnancy and asthma.While there is a natural reluctance to prescribe drug therapy in pregnancy, poorly controlled asthma is potentially more dangerous to the fetus than pharmacological therapy. Inhaled beta-agonists appear safe and should be used as required for symptomatic relief. Inhaled corticosteroids remain the mainstay of therapy. Beclomethasone has been used in pregnant patients for many years without signi¢cant adverse e¡ects. Less clinical experience in pregnancy is available for newer inhaled steroids such as budesonide and £uticasone, but these are associated with a lower level of systemic absorption. The use of a spacer device is encouraged to reduce local side-e¡ects and systemic absorption. While animal data suggest a small risk of cleft palate with systemic steroid use, this has not been demonstrated in humans. Short courses of prednisone are therefore recommended to manage poorly controlled asthma where clinically indicated. The management of
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CURRENT OBSTETRICS & GYNAECOLOGY an acute attack involves ensuring adequate oxygenation, close monitoring of the fetus, and appropriate drug therapy with nebulized bronchodilators and systemic steroid therapy. It is important that concerns for feta1 e¡ects of drugs do not cause physicians and patients to inappropriately avoid the use of e¡ective pharmacological therapy in symptomatic pregnant asthmatics. Asthma may have a number of deleterious e¡ects on pregnancy outcome. An increased incidence of preterm birth, low birthweight and increased prenatal mortality have all been reported, largely in the setting of poor asthma control. An acute exacerbation of asthma may be associated with signi¢cant hypoxaemia which may cause fetal compromise.
Lower respiratory tract infections
The pregnant patient is susceptible to the usual bacterial pathogens such as Streptococcus pneumoniae, Haemophilus in£uenzae and Mycoplasma pneumoniae, but also to a number of less common organisms. Pregnancy appears to be associated with a change in cell mediated immunity, predisposing the pregnant patient to develop pneumonitis from Varicella infection, and to an increased rate of dissemination of Coccidiomycosis. HIV infection and Pneumocystic carinii pneumonia should be considered in this patient group. Pregnancy does not appear to a¡ect the course or incidence of reactivation of tuberculosis.
A chest radiograph is essential for the diagnosis of lower respiratory tract infections, and should be considered in any pregnant woman with clinical features suggestive of pneumonia. Other diagnostic investigations include the microbiological cultures of blood and sputum, and serological tests for Legionella and Mycoplasma.
Management of bacterial pneumonia is with appropriate antibiotic therapy and supportive measures. Maternal pneumonia can be associated with fetal complications, with an increased preterm labour rate. Antibiotic therapy is similar to the non-pregnant patient although tetracyclines and quinolones should be avoided in pregnancy.Treatment of varicella pneumonia is with i.v. acyclovir, which decreases mortality and has not been associated with fetal anomalies.Transplacental transmission of varicella occurs uncommonly (55%) but can produce limb deformities and neurological involvement.The non-immune pregnant woman exposed to varicella should receive prophylaxis with zoster immune globulin within 96 h of exposure, and acyclovir if she develops clinical disease.Coccidiomycosis is associated with an extremely high mortality and disseminated disease should be treated with antifungal agents. Pneumocystis carinii pneumonia requires treatment with trimethoprim-sulfamethoxazole (with folate supplementation in pregnancy), as well as steroids if indicated clinically. While folic acid antagonists and sulphonamides carry risks for the fetus, pentamidine is associated with higher risks for both mother and fetus and should be avoided. Tuberculosis treatment is usually with isoniazid and rifampin, which have a low risk of adverse fetal e¡ects, as well as ethambutol (or pyrazinamide) until drug sensitivities are available. Unlike treatment of active disease, tuberculosis prophylaxis can usually be deferred until after pregnancy, except in the case of recent exposure or skin test conversion.
Adult Respiratory Distress Syndrome (ARDS)
The pregnant patient is at risk of developing ARDS from obstetric complications as well as being at increased risk of developing various non-obstetric conditions (Table 3) . Obstetric complications such as amniotic £uid embolism, chorioamnionitis, trophoblastic embolism, and placental abruption may result in acute lung injury and ARDS. Pregnancy predisposes to other pulmonary insults which can cause ARDS, including gastric aspiration, pneumonia, air embolism and massive haemorrhage. A predispo- sition to the development of ARDS in the presence of severe pyelonephritis has been described in pregnancy. Iatrogenic factors such as excessive £uid administration and tocolytic therapy may be partially responsible. It is important to remember that the serum albumin level (and therefore plasma oncotic pressure) is reduced in pregnancy, and this lowers the critical pulmonary capillary pressure at which pulmonary oedema develops. The diagnosis of ARDS is made by the presence of hypoxaemia with radiological evidence of di¡use pulmonary in¢ltrates, in the absence of cardiac failure. A detailed history is of most value in discerning the underlying process responsible.There are no major di¡erences in the management of the pregnant patient with ARDS. Management is supportive, with supplemental oxygen administration, mechanical ventilation when indicated, and the avoidance of iatrogenic complications. Fetal risk must be considered when pharmacological therapy is administered. Little data exist on the prolonged ventilatory management of pregnant patients, but consideration should be given to the normal physiological changes of pregnancy. Adequate maternal oxygen saturation is essential for fetal well-being. On the other hand, excessive ventilation with alkalosis may have adverse e¡ects on placental perfusion. Maternal acidosis appears to be reasonably well tolerated by the fetus. Delivery will be dictated by maternal and fetal factors, but may bene¢t both mother and child. In the unusual situation of a patient with severe ARDS in labour, epidural anaesthesia may provide a bene¢cial e¡ect by reducing the increased oxygen demand produced by uterine contractions.
While pregnancy produces increased oxygen requirements and may theoretically adversely a¡ect maternal outcome in ARDS, the survival actually appears to be similar to or better than that in the general population with ARDS. This may be due to the pregnant patients' youth and the reversibility of many predisposing conditions.
Other pulmonary conditions
Pleural disease
Pleural e¡usions may accompany obstetric complications such as pre-eclampsia and choriocarcinoma, but a significant proportion of women also develop small asymptomatic pleural e¡usions in the postpartum period. These result from the increased blood volume and reduced colloid osmotic pressure occurring in pregnancy, as well as impairment of lymphatic drainage by Valsalva manoevres during labour. Moderate size e¡usions or the presence of symptoms should prompt a full clinical evaluation. The repeated Valsalva manoeuvres of labour may also cause spontaneous pneumothorax and pneumomediastinum, particularly in patients with underlying predisposing conditions. This diagnosis should be considered in any pregnant patient who develops chest discomfort and dyspnoea during or immediately after delivery.
Interstitiallung disease
As many interstitial lung conditions have their onset beyond childbearing age, this is an uncommon association with pregnancy.The physiological changes in the respiratory system that accompany pregnancy do not signi¢-cantly a¡ect lung volumes in these patients. However, due to the reduced di¡using capacity, there may be di⁄-culty in meeting the increased oxygen consumption requirements of pregnancy. Little data exist on the management and outcome in these patients, but restrictive lung disease appears reasonably well tolerated in pregnancy. Women with a vital capacity less than 1 L and those with pulmonary hypertension should avoid pregnancy. Some conditions, notably lymphangioleiomyomatosis and SLE may deteriorate signi¢cantly during pregnancy.
Management involves the careful assessment and monitoring of respiratory and cardiovascular status. Exercise intolerance with oxygen desaturation is common. Supplemental oxygen therapy may be required to avoid hypoxaemic episodes which may be dangerous for the fetus. During labour, maternal e¡ort should be limited and oxygen saturation must be monitored.
Obstructive sleep apnoea
Pregnancy may be complicated by obstructive sleep apnoea (OSA), with potential adverse e¡ects for both the mother and fetus. In general, apnoea and hypopnoea are uncommon in pregnancy as progesterone acts as a respiratory stimulant.OSA occurs usually in obese patients where pregnancy produces airway mucosal oedema and engorgement. There appears to be an association between OSA and preeclampsia, probably related to the generalized oedema associated with this condition. Nocturnal hypoxaemia may adversely a¡ect the fetus, and poor fetal growth has been documented in these patients. Treatment with continuous positive airway pressure (CPAP) by nasal mask is safe and e¡ective. In contrast to obstructive sleep apnoea, snoring alone is not associated with fetal risk and is not a good marker for OSA.
Cystic ¢brosis
Advances in the management of patients with cystic ¢-brosis have extended life expectancy into the child-bearing age. Although fertility may be compromised, contraception and planned pregnancy should be considered in the management of these patients. The available data suggest that pregnancy does not increase mortality in patients with stable disease when compared with
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CURRENT OBSTETRICS & GYNAECOLOGY matched non-pregnant patients with cystic ¢brosis. Poor outcomes do occur in those patients with advanced disease. Those with a pre-pregnancy FVC less than 50% predicted or with pulmonary hypertension are at greatest risk. Perinatal mortality is increased, related largely to spontaneous preterm delivery or due to maternal complications of cystic ¢brosis. Management of the pregnant patient with cystic ¢brosis requires a multidisciplinary team, with careful attention to nutrition, glucose monitoring and genetic counselling. Respiratory exacerbations require early aggressive therapy, keeping in mind the potential fetal toxicity of antibiotics such as aminoglycosides and quinolones, and the altered maternal pharmacokinetics.
Gastric aspiration
Gastric acid aspiration may occur during labour due to delayed gastric emptying, reduced lower oesophageal sphincter tone and the e¡ects of increased intraabdominal pressure. Pulmonary e¡ects of aspiration result from particulate inhalation, bacterial infection and chemical pneumonitis (Mendelson's syndrome). The presentation of the chemical pneumonitis is with cough, bronchospasm and dyspnoea and can progress to ARDS. Prophylaxis with antacids, histamine-2 receptor antagonists or proton pump inhibitors is often given prior to Caesarean section. Treatment is supportive, with antibiotic therapy reserved for patients with evidence of infections, such as fever, sputum production and radiological changes.
Pulmonary vascular disease
Pulmonary arteriovenous malformations may expand during pregnancy due to the increase in blood volume and venous distensibility, increasing the likelihood of bleeding. Patients should be followed clinically and with serial chest radiographs. Embolisation and surgical management have been carried out successfully in pregnancy.
